Cargando…

The effect of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes

Patients with type 2 diabetes have a significantly increased risk of cardiovascular disease (CVD) compared to the general population—with CVD accounting for two out of every three deaths in patients with diabetes. In 2008, the FDA suggested that CVD risk should be evaluated for any new antidiabetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Dey, Amit K., Groenendyk, Jacob, Mehta, Nehal N., Gourgari, Evgenia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414247/
https://www.ncbi.nlm.nih.gov/pubmed/30635924
http://dx.doi.org/10.1002/clc.23152

Ejemplares similares